Stay updated with breaking news from Clinical Development Operations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry and Scientific Conferences in June 28.05.2024 / 12:30 CET/CEST The issuer is solely responsible
Immunic Inc (NASDAQ:IMUX) will be present at two conferences in June. At the BIO International Convention in San Diego, Jessica Breu, VP of Investor...
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle…
Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41%Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026Co-Founder and Board Director, Christopher Kirk, PhD, appointed...